NYSE:PFEPharmaceuticals
Pfizer Reshapes Portfolio With Metsera Deal And Obesity Oncology Pivot
Pfizer agreed to acquire Metsera for $10 billion, aiming to expand into obesity and weight loss drugs.
The company is reshaping its R&D focus toward metabolic disease, oncology and immunology.
Pfizer signed a licensing deal with Novavax for Matrix M adjuvant technology to support vaccine development.
Pfizer (NYSE:PFE), trading around $26.44, is trying to reposition itself after a difficult multi year share price period, with a reported 28.1% decline over 3 years and 2.8% decline over 5...